Indicaciones de rivaroxabán en diferentes situaciones clínicas

Abstract

Rivaroxaban is an oral highly selective direct factor Xa inhibitor. The main results of ROCKET-AF showed that in high risk patients with nonvalvular atrial fibrillation, rivaroxabán was noninferior to warfarin for the prevention of stroke or systemic embolism, but with lesser risk of intracranial and fatal bleeding. Remarkably, rivaroxaban has been proven to be effective and safe in patients with renal dysfunction, elderly patients as well as in those with ischemic heart disease or previous stroke. Rivaroxaban is taken only once daily. Compared with other new oral anticoagulants, this may provide better compliance and medication adherence and, consequently, a reduction in the risk of stroke during the follow-up. Moreover, the interactions with other drugs are low. This together with the once daily dose makes rivaroxabán an excellent alternative for the prevention of thromboembolic events in polymedicated patients with atrial fibrillation. This manuscript reviews the available evidence about the efficacy and safety of rivaroxabán in patients with atrial fibrillation in different clinical settings.